Long-term safety of approved biologics for ulcerative colitis.
Fiche publication
Date publication
mai 2020
Journal
Expert opinion on drug safety
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) affecting the large intestine and carrying a heavy burden of morbidity for patients. Conventional treatment is based on mesalamine, corticosteroids, and immunosuppressants. In the last two decades, biologic therapies have revolutionized the treatment of UC, increasing the number of therapeutic options and providing better disease control.
Mots clés
adalimumab, golimumab, infliximab, long-term safety, ulcerative colitis, ustekinumab, vedolizumab
Référence
Expert Opin Drug Saf. 2020 May 22;: